Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Rocket Pharmaceuticals, Inc. Common Stock (RCKT)

Pharmaceutical Preparations

https://www.rocketpharma.com

Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

350 FIFTH AVENUE, SUITE 7530
NEW YORK, NY

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/18/2015

Market Cap

1,685,783,427

Shares Outstanding

90,160,000

Weighted SO

90,158,895

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

QURE --.--%

RYTM --.--%

SLDB --.--%

MGTX --.--%

PCVX --.--%

LRMR --.--%

SNDX --.--%

MRUS --.--%

STRO --.--%

Beta

1.1280

Last Div

0.0000

Range

14.89-32.525

Chg

-0.0700

Avg Vol

841214

Mkt Cap

1685783427

Exch

NASDAQ

Country

US

Phone

609 659 8001

DCF Diff

18.0926

DCF

0.3674

Div Yield

0.0000

P/S

163.4778

EV Multiple

-6.4549

P/FV

4.5163

Div Yield %

0.0000

P/E

-6.8591

PEG

-0.7362

Payout

0.0000

Current Ratio

7.7869

Quick Ratio

7.7869

Cash Ratio

1.0270

DSO

286.7048

DIO

0.0000

Op Cycle

286.7048

DPO

0.0000

CCC

286.7048

Gross Margin

-0.1162

Op Margin

-26.1632

Pretax Margin

-24.5596

Net Margin

-24.5596

Eff Tax Rate

0.0005

ROA

-0.5673

ROE

-0.5447

ROCE

-0.6599

NI/EBT

1.0000

EBT/EBIT

0.9387

EBIT/Rev

-26.1632

Debt Ratio

0.0578

D/E

0.0671

LT Debt/Cap

0.0563

Total Debt/Cap

0.0629

Int Coverage

-269795.0000

CF/Debt

-7.6449

Equity Multi

1.1606

Rec Turnover

1.2731

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.1178

Asset Turnover

0.0231

OCF/Share

-2.1038

FCF/Share

-2.2453

Cash/Share

2.9743

OCF/Sales

-19.1255

FCF/OCF

1.0673

CF Coverage

-7.6449

ST Coverage

-68.9829

CapEx Coverage

-14.8656

Div&CapEx Cov

-14.8656

P/BV

4.5163

P/B

4.5163

P/S

163.4778

P/E

-6.8591

P/FCF

-8.0089

P/OCF

-8.8079

P/CF

-8.8079

PEG

-0.7362

P/S

163.4778

EV Multiple

-6.4549

P/FV

4.5163

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 26, 00:12 Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman GlobeNewswire Inc. Jun 21, 14:30 INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEM GlobeNewswire Inc. Jun 19, 20:00 RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Benzinga Jun 18, 23:30 Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz GlobeNewswire Inc. Jun 17, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, PepGen, Tempus, and Rocket and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jun 14, 01:00 ROCKET ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Rocket Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jun 14, 00:28 RCKT Investor Notice: Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Rocket Pharmaceuticals, Inc. GlobeNewswire Inc. Jun 12, 00:09 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Rocket Pharmaceuticals, Inc. Securities and Sets a Lead Plaintiff Deadline of August 11, 2025 GlobeNewswire Inc. May 29, 22:44 Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm GlobeNewswire Inc. May 29, 22:39 Tempus AI, Inc. Investors: Company Investigated by the Portnoy Law Firm GlobeNewswire Inc. May 28, 22:25 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT GlobeNewswire Inc. Jul 30, 06:00 Global Regenerative Medicine Market Size To Worth USD 349.93 Billion By 2033 | CAGR of 27.06% Benzinga Oct 24, 11:00 Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023

Revenue Product Segmentation